Brian Orelli, PhD

Analyst upgrades add fuel to the fire.

FDA approval of Novartis' CAR-T therapy bodes well for the biotech, even if it was widely expected.

An FDA "breakthrough therapy" designation for Abeona's gene therapy sent shares of the company higher, but investors should focus on the bigger picture.

A deal with Jazz Pharmaceuticals has investors dancing the Lindy hop.

The biotechs' surge is related to a big move for fellow immuno-oncology drug developer Kite Pharma.

FDA approvals tend to make investors happy.

A solid-enough second quarter from the diabetes specialist boosts investors' confidence in a turnaround.

Next month's phase 3 data are much more important than the biotech's second-quarter earnings release.

A solid second quarter from the biotech, with growing royalties on Spinraza and two more drugs to be reviewed by regulators, and it regained full rights to two drugs after its partner declined to license them.

Analysts upped their price targets following a solid second-quarter report from the drugmaker.

After losing some contracts, the specialty pharmacy company has been able to replace that revenue, setting itself up for growth next year.

A solid second quarter from the drugmaker.

On an adjusted basis, the medical and science supply company is doing fine.

Positive phase 2 data for the company's lung drug increases the biotech's value.

Three newly acquired products.

With the ASCO and EHA conferences behind it, the biotech looks to ASH to end the year with a bang.

Cabometyx is still in hypergrowth, and approvals for additional indications could be here shortly.

Analyst downgrades are sinking shares of the generic-drug maker.

The biotech produced growing drug sales, won an FDA and EMA approval, filed a marketing application for another drug, and released promising on data on pipeline candidates.

The drug distributor sees pressure on drug prices.